{
  "id": 268547,
  "title": "‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit",
  "url": "https://urgent.news/2026/08/07/significant-demand-for-revolution-drug-intellia-pinpoints-liver",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T14:02:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/daraxonrasib-compassionate-use-intellia-arrowhead-cspc-vedanta/827186/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Intellia identifies genetic risk factor for liver complications in CRISPR trial",
        "url": "https://urgent.news/2026/08/06/intellia-identifies-genetic-risk-factor-for-liver-complications-in",
        "published": "2026-08-06T15:33:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}